Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

This study aims to understand how your genes might affect how much weight you lose when using the medication naltrexone-bupropion. Researchers want to see if specific genetic differences are linked to better weight loss results. You could be eligible if you are between 18 and 65 years old and have a BMI (Body Mass Index) of 30-50 kg/m2, or a BMI of 27-29.99 kg/m2 with certain weight-related health issues like controlled high blood pressure. The main goal is to measure your percentage of weight loss over 40 weeks. This study is currently unclear on its recruitment status and plans to enroll 120 participants.

Study design: This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 120 participants.
What's involved: Participants will receive naltrexone-bupropion medication for 28 weeks during phase two of the study.
Compensation: Not stated in the trial record.
Follow-up: Your weight loss will be measured at baseline and again at 40 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Recruiting

PHASE4Ages 18–65Interventional

Columbia University

~120 participants

Updated 2026-06-10 on ClinicalTrials.gov

What's tested:Naltrexone-Bupropion Combination

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Percent Weight Loss (40 Weeks)

Measured over Baseline and 40 Weeks

Conditions

Obesity

Where it's being run

1 sites across 1 states

New York1

Study leadership

Judith Korner, MD,PhD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Judith Korner, MD,PhD

[email protected]

212-305-4006

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Men and women ages 18-65 years

BMI 30-50 kg/m2 or

BMI 27-29.99 kg/m2 with at least one weight-related comorbidity including controlled hypertension, dyslipidemia, obstructive sleep apnea, or osteoarthritis of a weight-bearing joint.

Exclusion

Obesity of known endocrine or hypothalamic origin

HbA1c \> 6.5%

Cerebrovascular, cardiovascular, hepatic or renal disease

History of seizures, serious psychiatric illness or suicide attempts, drug or alcohol misuse within prior 24 months

Glaucoma

Current tobacco use on a regular basis

Use of dopamine agonists, opioid analgesics, antipsychotics, antidepressants, neuroleptics, naltrexone, diabetes medications

Use of Monoamine oxidase (MAO) inhibitors \< 14 days prior to screening

Concomitant use of CYP2B6 inhibitors

History of anorexia nervosa or bulimia

Previous surgery for obesity

Weight loss device intervention within prior 2 years

Currently pregnant or lactating, planning pregnancy or refusal to use birth control when appropriate (Women of childbearing potential will be required to use effective contraception.)

Blood pressure \> 145/95 (use of anti-hypertensives will be allowed with the exception of verapamil, which can cause hyperprolactinemia)

Clinically significant thyroid disease

Triglycerides \> 499 mg/dl

Current use or use of weight loss medication within prior six months

Any lifetime weight change deemed significant by Principal Investigator

An affirmative answer to any question in the Columbia-Suicide Severity Rating Scale

What this trial measures

Percent Weight Loss (40 Weeks)Baseline and 40 Weeks
Percent weight loss from baseline to 40 weeks.

Trialytics